Hernández-Becerril N, Nava A, Reyes PA, Monteón VM

Language: English
References: 27
Page: 199-205
PDF size: 71.33 Kb.

ABSTRACT

Background: The anti-Trypanosoma cruzi antibodies isotype profile in Chagas’ disease has been studied in relation to different clinical manifestations. A high titer of IgG anti-T. cruzi antibodies is found in patients with cardiac involvement, while a high titer of IgA anti-T. cruzi antibodies is associated with digestive forms. Objective: The aim of this work was to analyze the IgG subclass reactivity of anti-T. cruzi antibodies in patients with chronic Chagasic cardiomyopathy. Methods: Twelve consecutive chagasic patients were analyzed for IgG subclass reactivity to a T. cruzi antigenic extract. They had a complete clinical evaluation, peripheral EKG, echocardiography, left ventriculogram, and coronariography. Results: All patients came from rural areas of Mexico and had lived in endemic zones for over seven years. They presented left ventricular end-systolic dimension above 42 mm in 58% (7/12) and ejection fraction below 50% in 58% (7/12). We found that IgG1 and IgG2 anti-T. cruzi antibodies showed higher titer than IgG3 antibodies, with consistently low titer of IgG4 antibodies. Expression of the four IgG subclasses of anti-T. cruzi antibodies suggest a mixed Th1/Th2-like immune response under a probably continuous chronic antigenic stimulation. On the other hand, high levels of IgG2 anti-T. cruzi antibodies showed a tendency to be associated with severe cardiomegaly. Conclusions: Our results suggest that a mixed Th1/Th2-like immune response may take place in chronic chagasic patients under a chronic antigenic stimulation.

REFERENCES

1. Rassi A, Luquetti O, Rassi A, Rassi SG., Rassi AG: Chagas disease clinical features. In: Chagas’ disease (American Trypanosomiasis): Its impact on transfusion and Clinical medicine. Is BT Brazil, 92, Sao Paulo Brazil.1992; 81-101.

2. Krettli A, Brener Z: Protective effects of specific antibodies in Trypanosoma cruzi associated to anti - living trypomastigotes antibodies. J Immunol 1976; 116: 755-760.

3. Norris K, Harth G, So M: Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies. Inf Immun 1989; 87: 2372-2377.

4. Takehara HA, Perini A, Da Silva M, Mota I: Trypanosoma cruzi. Role of different antibody classes in protection against infection in the mouse. Exp Parasitol 1981; 52: 137-141.

5. Powell M, Wassom D: 1993. Host genetics and resistance to acute Trypanosoma cruzi infection in mice. I. Antibody isotype profiles. Parasite Immunol 1993; 15: 215-221

6. Primavera K, Hoshino-Shimizu S, Umezawa E, Peres B, Manigot D, Camargo M: Immunoglobulin A antibodies to Trypanosoma cruzi antigens in digestive forms of Chagas’ disease. J Clin Microbiol 1988; 26: 2101-2104.

7. Cerban F, Gea S., Menso E, Vottero-Cima E. Chagas’ disease: IgG isotypes against Trypanosoma cruzi cytosol acidic antigens in patients with different degree of heart damage. Clin Immunol Immunopathol 1993; 67: 25-30.

8. 8. Umezawa E, Shikanai-Yasuda M, Stolf M. Changes in isotype composition and antigen recognition of anti- Trypanosoma cruzi antibodies from acute to Chronic Chagas disease. Journ Clin Lab Analy 1996; 10: 407-413.

9. Levin MJ, Levitus G, Kerner N, Lafon S, Schijman A, Levy-Yeyatic P, et al: Autoantibodies in Chagas’ disease: possible markers of severe Chagas’ heart complaint. Mem Inst Oswaldo Cruz 1990; 85: 539-543.

10. Skyllouriotis P, Skyllourioti-Lazarou M, Natter S, Steiner S, Spitzauer S, Kapiotis S, et al: IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of Th1-like autoimmune disease. Clin Expe Immunol 1999; 115: 236-247.

11. Ramos-Echevarría A, Monteón VM, Reyes PA: Detección de anticuerpos contra Trypanosoma cruzi en donadores de sangre. Sal Publ (Mex) 1993; 3556-64.

12. Vázquez-Abad D, Monteón V, J Senecal J, Walsh SN, Rothfield N: Analysis of IgG Subclasses of human topoisomerase I. Autoantibodies suggests Chronic B cell stimulation. Clin Immunol Immunopathol 1997; 84: 65-72.

13. Hamilton R: Human IgG measurements in the clinical laboratory. Clin Chem 1987; 33: 1707-1725.

14. Higuchi M, Britto T, Reiss M, Barbosa A, Belloti G, Pereira-Barreto A, Pileggi F: Correlation between Trypanosoma cruzi parasitism and myocardium inflammatory infiltrate in human Chronic Chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol 1993; 2: 101-106

15. Monteón–Padilla VM, Hernández-Becerril N, Ballinas-Verdugo MA, Aranda Fraustro A, Reyes PA: Persistence of Trypanosoma cruzi in chronic chagasic cardiopathy patients. Arch Med Res 2001; 32: 39-43

16. Jones E, Colley D, Reis E, Vnencak-Colley C, McCurley T: Amplification of Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 1993; 48: 348-357

17. Callard R: Immunoregulation by interleukin-4 in man. Br. Journ Haemathol 1991; 78: 293-299.

18. Lundren M, Persson V, Larsson P:Interleukin-4 induces synthesis of IgE and IgG4 in human B cells. Eur Journ Immunol 1989 19: 1311-1315.

19. Jefrris R: Selective IgG subclass deficiency: Quantification and clinical relevance. Clin Exp Immunol 1990; 81: 357-367.

20. German T, Bongartz M, Dlugonska H:Interleukin-12 profoundly up-regulate the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclass in vivo. Eur Journ Immunol 1995; 25: 823-829.

21. Chrlton B, Lafferty KJ: The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995; 7:793-798

22. Samudio M, Montenegro-James S, de Cabral M, Martínez J, Rotas A et al: Differential expression of systemic cytokine profiles in Chagas‘disease is associated with endemicity of Trypanosoma cruzi infection. Acta Trop 1998; 69:89-97

23. Dutra W, Gollob K, Pinto-Dias J, Gazzinelli G, Correa-Oliverira R et al: Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand Journ Immunol 1997;45:74-80.

24. Monteón-Padilla V, Hernández-Becerril N, Guzmán-Bracho C, Rosales-Encina JI, Reyes PA: American trypanosomiasis (Chagas‘disease) and blood banking in México City: Seroprevalence and its potential transfusional transmission risk. Arch Med Res 1999; 30: 393-398.

25. Nicholson LB, Kuchroo VK: Manipulation of the Th1/TH2 balance in autoimmune disease. Autoimmunity 1996; 8: 837-842.

26. Morgan J, Pinto JC, Dias E, Bahia-Oliveira L, Correa-Oliveira R, Colley D, et al: Anti-Trypanosma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas´ disease. Am J Trop Med Hyg 1996;55:355-359

27. Cordeiro FD, Martins-Filho O, Da Costa MO, Adad SJ, Correa-Oliveira R, et al: Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas‘disease. Clin Diagn Lab Immunol 2001;8:112-118.